*Corresponding author:Daniela Vazquez Capdepón, Medical Director of the Centro Oncológico campana, Oncologist of the Perú Hospital Gral. Galarza, Oncologist of the Centro Medico San José, French 374 – Campana, Pacia. BS. AS.
Received: June 06, 2017 Published: June 09, 2017
To view the Full Article Peer-reviewed Article PDF
Lung cancer is the most common cause of cancer death in Western countries, and non-small cell lung cancer (NSCLC) accounts for 80% of these neoplasms. Despite the efforts in the early diagnosis and advances in the treatment of these patients, overall survival remains very low, approximately 18% at 5 years2. The relatively low (30-50%) survival of patients with limited, potentially curable disease probably reflects the inability to detect advanced disease at initial staging